纤维蛋白原、NLR及F-NLR评分在胃癌中的研究进展

doi:10.3760/cma.j.cn371439-20201230-00083

摘要/Abstract

摘要：

胃癌相关的多种标志物已被广泛用于临床,可预测其发生、发展及预后。血清纤维蛋白原水平及中性粒细胞-淋巴细胞比值(NLR)分别作为凝血系统及炎症的代表性指标,可预测胃癌患者的预后和生存时间。纤维蛋白原水平的升高与胃肿瘤细胞的增殖、侵袭和迁移能力的增强有显著的相关性;高NLR和胃癌患者的生存期缩短密切相关。由二者联合的F-NLR评分结合了两者在预测胃癌的发生、发展和转归中的优点,在胃癌预后预测等方面显示出了良好的应用价值,具有广阔的应用前景。

关键词: 胃肿瘤, 纤维蛋白原, 预后, 中性粒细胞与淋巴细胞比值

Abstract:

Multiple markers that related to gastric cancer has been widely used in clinical, to predict its occurrence, development and prognosis. Serum level of fibrinogen (FIB) and neutrophil to lymphocytes ratio (NLR) respectively as representative indicators of coagulation system and inflammation, can predict the prognosis of patients with gastric cancer and survival time. The rise of fibrinogen is associated with enhanced capacity of the gastric tumor cells proliferation, invasion and migration. High NLR is associated with significantly induced survival of patients with gastric cancer. The combination of fibrinogen and NLR (F-NLR) combines the advantages of each individual indicator in predicting the occurrence, development and prognosis of cancer. It has shown a great prognostic potential in gastric cancer, and can be widely applied in prospect.

Key words: Stomach neoplasms, Fibrinogen, Prognosis, Neutrophil to lymphocyte ratio

杨银静, 李桂香, 唐敏. 纤维蛋白原、NLR及F-NLR评分在胃癌中的研究进展[J]. 国际肿瘤学杂志, 2021, 48(7): 433-435.

Yang Yinjing, Li Guixiang, Tang Min. Research progress of fibrinogen, NLR and F-NLR grading in gastric cancer[J]. Journal of International Oncology, 2021, 48(7): 433-435.

参考文献 29

[1]	Thrift AP, El-Serag HB. Burden of gastric cancer[J]. Clin Gastroenterol Hepatol, 2020, 18(3):534-542. DOI: 10.1016/j.cgh.2019.07.045. doi: 10.1016/j.cgh.2019.07.045
[2]	Arnold M, Abnet CC, Neale RE, et al. Global burden of 5 major types of gastrointestinal cancer[J]. Gastroenterology, 2020, 159(1):335-349, e15. DOI: 10.1053/j.gastro.2020.02.068. doi: 10.1053/j.gastro.2020.02.068
[3]	Chen L, Yan Y, Zhu L, et al. Systemic immune-inflammation index as a useful prognostic indicator predicts survival in patients with advanced gastric cancer treated with neoadjuvant chemotherapy[J]. Cancer Manag Res, 2017, 9:849-867. DOI: 10.2147/CMAR.S151026. doi: 10.2147/CMAR.S151026 pmid: 29276407
[4]	Kurokawa Y, Doki Y, Mizusawa J, et al. Bursectomy versus omentectomy alone for resectable gastric cancer (JCOG1001): a phase 3, open-label, randomised controlled trial[J]. Lancet Gastroenterol Hepatol, 2018, 3(7):460-468. DOI: 10.1016/S2468-1253(18)30090-6.
[5]	Moons KG, Altman DG, Reitsma JB, et al. Transparent Reporting of a multivariable prediction model for Individual Prognosis or Diagnosis (TRIPOD): explanation and elaboration[J]. Ann Intern Med, 2015, 162(1):W1-W73. DOI: 10.7326/M14-0698. doi: 10.7326/M14-0698
[6]	Matsuoka T, Yashiro M. Biomarkers of gastric cancer: current topics and future perspective[J]. World J Gastroenterol, 2018, 24(26):2818-2832. DOI: 10.3748/wjg.v24.i26.2818. doi: 10.3748/wjg.v24.i26.2818
[7]	Karki R, Man SM, Kanneganti TD. Inflammasomes and cancer[J]. Cancer Immunol Res, 2017, 5(2):94-99. DOI: 10.1158/2326-6066.CIR-16-0269. doi: 10.1158/2326-6066.CIR-16-0269
[8]	Yu X, Hu F, Yao Q, et al. Serum fibrinogen levels are positively correlated with advanced tumor stage and poor survival in patients with gastric cancer undergoing gastrectomy: a large cohort retrospective study[J]. BMC Cancer, 2016, 16:480. DOI: 10.1186/s12885-016-2510-z. doi: 10.1186/s12885-016-2510-z
[9]	Miyamoto R, Inagawa S, Sano N, et al. The neutrophil-to-lymphocyte ratio (NLR) predicts short-term and long-term outcomes in gastric cancer patients[J]. Eur J Surg Oncol, 2018, 44(5):607-612. DOI: 10.1016/j.ejso.2018.02.003. doi: S0748-7983(18)30296-8 pmid: 29478743
[10]	Cong X, Li S, Zhang Y, et al. The combination of preoperative fibrinogen and neutrophil-lymphocyte ratio is a predictive prognostic factor in esophagogastric junction and upper gastric cancer[J]. J Cancer, 2019, 10(22):5518-5526. DOI: 10.7150/jca.31162. doi: 10.7150/jca.31162
[11]	Repetto O, De Re V. Coagulation and fibrinolysis in gastric cancer[J]. Ann N Y Acad Sci, 2017, 1404(1):27-48. DOI: 10.1111/nyas.13454. doi: 10.1111/nyas.13454
[12]	Lin Y, Liu Z, Qiu Y, et al. Clinical significance of plasma D-dimer and fibrinogen in digestive cancer: a systematic review and meta-analysis[J]. Eur J Surg Oncol, 2018, 44(10):1494-1503. DOI: 10.1016/j.ejso.2018.07.052. doi: 10.1016/j.ejso.2018.07.052
[13]	Wang H, Zhao J, Zhang M, et al. The combination of plasma fibri-nogen and neutrophil lymphocyte ratio (F-NLR) is a predictive factor in patients with resectable non small cell lung cancer[J]. J Cell Physiol, 2018, 233(5):4216-4224. DOI: 10.1002/jcp.26239. doi: 10.1002/jcp.v233.5
[14]	Sun Y, Zhang Y, Huang Z, et al. Combination of preoperative plasma fibrinogen and neutrophil-to-lymphocyte ratio (the F-NLR score) as a prognostic marker of locally advanced rectal cancer following preoperative chemoradiotherapy[J]. World J Surg, 2020, 44(6):1975-1984. DOI: 10.1007/s00268-020-05407-3. doi: 10.1007/s00268-020-05407-3
[15]	Yamamoto M, Kurokawa Y, Kobayashi N, et al. Prognostic value of the combined index of plasma fibrinogen and the neutrophil-lymphocyte ratio in gastric cancer[J]. World J Surg, 2020, 44(1):207-212. DOI: 10.1007/s00268-019-05193-7. doi: 10.1007/s00268-019-05193-7 pmid: 31559484
[16]	Grafetstätter M, Hüsing A, González Maldonado S, et al. Plasma fibrinogen and sP-selectin are associated with the risk of lung cancer in a prospective study[J]. Cancer Epidemiol Biomarkers Prev, 2019, 28(7):1221-1227. DOI: 10.1158/1055-9965.EPI-18-1285. doi: 10.1158/1055-9965.EPI-18-1285
[17]	Yamamoto M, Kurokawa Y, Miyazaki Y, et al. Usefulness of preo-perative plasma fibrinogen versus other prognostic markers for predicting gastric cancer recurrence[J]. World J Surg, 2016, 40(8):1904-1909. DOI: 10.1007/s00268-016-3474-5. doi: 10.1007/s00268-016-3474-5 pmid: 26969673
[18]	Huang C, Liu Z, Xiao L, et al. Clinical significance of serum CA125, CA19-9, CA72-4, and fibrinogen-to-lymphocyte ratio in gastric cancer with peritoneal dissemination[J]. Front Oncol, 2019, 9:1159. DOI: 10.3389/fonc.2019.01159. doi: 10.3389/fonc.2019.01159 pmid: 31750248
[19]	Crusz SM, Balkwill FR. Inflammation and cancer: advances and new agents[J]. Nat Rev Clin Oncol, 2015, 12(10):584-596. DOI: 10.1038/nrclinonc.2015.105. doi: 10.1038/nrclinonc.2015.105
[20]	Chmiela M, Karwowska Z, Gonciarz W, et al. Host pathogen inte-ractions in Helicobacter pylori related gastric cancer[J]. World J Gastroenterol, 2017, 23(9):1521-1540. DOI: 10.3748/wjg.v23.i9.1521. doi: 10.3748/wjg.v23.i9.1521
[21]	Piciucchi M, Stigliano S, Archibugi L, et al. The neutrophil/lymphocyte ratio at diagnosis is significantly associated with survival in metastatic pancreatic cancer patients[J]. Int J Mol Sci, 2017, 18(4):730. DOI: 10.3390/ijms18040730. doi: 10.3390/ijms18040730
[22]	Yodying H, Matsuda A, Miyashita M, et al. Prognostic significance of neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio in oncologic outcomes of esophageal cancer: a systematic review and meta-analysis[J]. Ann Surg Oncol, 2016, 23(2):646-654. DOI: 10.1245/s10434-015-4869-5. doi: 10.1245/s10434-015-4869-5
[23]	Li S, Lan X, Gao H, et al. Systemic inflammation response index (SIRI), cancer stem cells and survival of localised gastric adenocarcinoma after curative resection[J]. J Cancer Res Clin Oncol, 2017, 143(12):2455-2468. DOI: 10.1007/s00432-017-2506-3. doi: 10.1007/s00432-017-2506-3
[24]	Kwon BS, Jeong DH, Byun JM, et al. Prognostic value of preoperative lymphocyte-monocyte ratio in patients with ovarian clear cell carcinoma[J]. J Cancer, 2018, 9(7):1127-1134. DOI: 10.7150/jca.24057. doi: 10.7150/jca.24057
[25]	Cupp MA, Cariolou M, Tzoulaki I, et al. Neutrophil to lymphocyte ratio and cancer prognosis: an umbrella review of systematic reviews and meta-analyses of observational studies[J]. BMC Med, 2020, 18(1):360. DOI: 10.1186/s12916-020-01817-1. doi: 10.1186/s12916-020-01817-1
[26]	Foley JH, Conway EM. Cross talk pathways between coagulation and inflammation[J]. Circ Res, 2016, 118(9):1392-1408. DOI: 10.1161/CIRCRESAHA.116.306853. doi: 10.1161/CIRCRESAHA.116.306853
[27]	Liu X, Liu Z, Lin E, et al. A cumulative score based on preoperative fibrinogen and the neutrophil-lymphocyte ratio to predict outcomes in resectable gastric cancer[J]. Cancer Manag Res, 2018, 10:3007-3014. DOI: 10.2147/CMAR.S174656. doi: 10.2147/CMAR
[28]	Tianxing G, Xiaojie P, Lihuan Z, et al. Combination of preoperative fibrinogen and neutrophil to lymphocyte ratio is a predictive prognostic factor in ESCC and AEG systematic review[J]. Biosci Rep, 2019, 39(10): BSR20190480. DOI: 10.1042/BSR20190480.
[29]	Yang J, Ma J, Cheng S, et al. The combination of plasma fibrinogen concentration and neutrophil lymphocyte ratio (F-NLR) as a prognostic factor of epithelial ovarian cancer[J]. Onco Targets Ther, 2020, 13:7283-7293. DOI: 10.2147/OTT.S264118. doi: 10.2147/OTT.S264118